Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Verve Therapeutics, Inc.

Verve Therapeutics is a clinical-stage biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. In 2023, Verve was recognized as a "Best Places to Work" by the Boston Globe. Verve is headquartered in Boston, Massachusetts. 

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover				0.00 -	0.02 446.64%
cash conversion cycle					-260.96 -
cash per share	1.06 -	4.07 283.94%	13.41 229.97%	31.28 133.17%	9.72 68.91%
company equity multiplier	-1.11 -	-1.23 10.83%	1.07 187.61%	1.23 14.69%	1.26 1.84%
days of inventory outstanding
days of payables outstanding					444.02 -
days of sales outstanding				190.30 -	183.06 3.81%
dividend yield
ebit per revenue				-85.36 -	-18.98 77.77%
ebt per ebit	1.41 -	1.12 20.47%	1.38 22.84%	0.95 31.28%	0.90 5.70%
effective tax rate	0.01 -	0.00 75.40%	0.01 293.24%	-0.00 102.42%	-0.00 308.60%
enterprise value multiple	-41.61 -	-14.18 65.92%	-10.66 24.80%	-1.90 82.16%	-3.51 84.40%
fixed asset turnover				0.02 -	0.11 521.81%
free cash flow per share	-0.52 -	-2.18 316.06%	-3.06 40.32%	-7.64 149.70%	-2.47 67.61%
gross profit margin				1 -	0.54 46.39%
interest coverage				19.84 -
inventory turnover
long term debt to capitalization				0.11 -	0.10 13.59%
net income per ebt	0.99 -	1.00 1.10%	0.99 1.04%	1.00 1.45%	1.00 0.10%
net profit margin				-81.09 -	-17.02 79.02%
operating cash flow per share	-0.42 -	-1.99 373.86%	-2.90 45.79%	-6.90 137.94%	-2.33 66.21%
operating cycle					183.06 -
operating profit margin				-85.36 -	-18.98 77.77%
payables turnover					0.82 -
pretax profit margin				-81.06 -	-16.99 79.04%
price fair value	-28.96 -	-8.86 69.40%	2.77 131.29%	0.62 77.53%	1.49 139.51%
receivables turnover				1.92 -	1.99 3.96%
return on assets	-0.88 -	-0.58 33.90%	-0.31 46.82%	-0.23 24.97%	-0.27 14.71%
return on capital employed	-0.75 -	-0.57 24.21%	-0.24 57.92%	-0.26 6.98%	-0.31 21.20%
return on equity	0.97 -	0.71 26.74%	-0.33 146.59%	-0.29 13.95%	-0.33 16.82%
total debt to capitalization			0.01 -	0.13 2,279.02%	0.11 14.19%

COM:VERVETX

Vervet Logic, Inc.

Last Close

4.60

22/11 21:00

Market Cap

507.99M

Beta: -

Volume Today

1.12M

Avg: -

Preview